| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5588051 | Journal of Diabetes and its Complications | 2017 | 34 Pages |
Abstract
Dapagliflozin produced clinically meaningful reductions in HbA1c, weight, and SBP in patients with T2DM and HF, and was well tolerated.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu, Christian Sonesson, Eva Johnsson,